AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
With the development of <sup>68</sup>Ga and <sup>177</sup>Lu radiochemistry, theranostic approaches in modern nuclear medicine enabling patient-centered personalized medicine applications have been growing in the last decade. In conjunction with the search for new relevant mo...
Saved in:
Main Authors: | Cyril Fersing (Author), Nicolas Masurier (Author), Léa Rubira (Author), Emmanuel Deshayes (Author), Vincent Lisowski (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents
by: Prisca Lagardère, et al.
Published: (2021) -
<sup>225</sup>Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
by: Léa Rubira, et al.
Published: (2023) -
Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators
by: Cyril Fersing, et al.
Published: (2021) -
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
by: Melpomeni Fani, et al.
Published: (2017) -
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
by: Cristina Barca, et al.
Published: (2021)